OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.910
-0.100 (-4.98%)
At close: Dec 5, 2025, 4:00 PM EST
1.900
-0.010 (-0.52%)
After-hours: Dec 5, 2025, 4:51 PM EST
OKYO Pharma Employees
OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,176,573
Market Cap
71.84M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OKYO News
- 14 days ago - OKYO Pharma Announces Chairman and Founder Acquires Shares - GlobeNewsWire
- 17 days ago - OKYO Pharma to Present at OIS XV in San Diego - GlobeNewsWire
- 2 months ago - OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain - GlobeNewsWire
- 5 months ago - OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
- 6 months ago - Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - Accesswire
- 7 months ago - OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewsWire
- 7 months ago - OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
- 8 months ago - OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewsWire